Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02878564

Recruitment Status : Completed

First Posted : August 25, 2016

Last Update Posted : October 27, 2016

Sponsor:

Collaborator:

UVRI-IAVI HIV Vaccine Program, Uganda

Information provided by (Responsible Party):

Rupert Kaul, University of Toronto

Study Description

Brief Summary:

The aim of this study is to assess the impact of Schistosoma mansoni infection and its treatment on genital immunology and HIV susceptibility in Ugandan women.

Condition or disease	Intervention/treatment	Phase
Schistosomiasis Mansoni HIV	Drug: Praziquantel	Phase 4

Detailed Description:

Schistosomiasis mansoni is a water-borne disease caused by helminth Schistosoma mansoni (S. mansoni), in which adult worms deposit eggs in mesenteric blood vessels. Schistomiasis prevalence in the fishing communities in East Africa, and particularly in the Lake Victoria region, exceeds 60% and there is overlap in this region with a high prevalence of HIV (29%).

A recent epidemiological study found an association between S. mansoni and HIV infection in adult women residing near Lake Victoria in Tanzania. Furthermore, in primate studies S. mansoni infection was shown to increase susceptibility to SIV infection after rectal (but not intravenous) challenge, implying that S. mansoni might increase HIV susceptibility by altering local mucosal (gut) immunology.

While S. mansoni does not directly infect the genital tract, we hypothesize that the inflammation it causes in the gut may be associated with mucosal inflammation at other sites through activation of common mucosal homing integrins such as a4b7. Therefore in this study we propose to explore whether S. mansoni increases inflammation and/or HIV susceptibility in the endocervix of adult women.

HIV-uninfected adult women from Entebbe, Uganda will be screened for schistosomiasis using a commercial CCA rapid test kit, and infected women who fulfill the study eligibility criteria will be recruited into the study. Kato-Katz microscopy analysis will be performed to assess egg shedding at baseline. Additionally, urine microscopy will be done to screen for Schistosoma hematobium (which can directly involve the genital mucosa). Schistosomiasis treatment will be provided to all participants according to Ugandan clinical guidelines.

Endocervical cytobrush, vaginal SoftCup and blood samples will be collected at three time points; at baseline and 4 and 8 weeks after schistosomiasis treatment, at the same stage of the menstrual cycle. Using an ex vivo HIV entry assay and mucosal cytokine and microbiome analyses we will quantify the effect of S. mansoni and its treatment on cervical HIV susceptibility and genital inflammation.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	34 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology
Study Start Date :	March 2016
Actual Primary Completion Date :	October 2016
Actual Study Completion Date :	October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Praziquantel

Genetic and Rare Diseases Information Center resources: Schistosomiasis Helminthiasis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Praziquantel treatment Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.	Drug: Praziquantel 40 mg/kg, PO (orally administered tablets) Other Name: Agopraz, bromoxel, biltricide

Outcome Measures

Primary Outcome Measures :

Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis. [ Time Frame: 1 month. ]
The percentage of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.
Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis. [ Time Frame: 1 month. ]
The number of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.

Secondary Outcome Measures :

Change in the percentage of blood CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis. [ Time Frame: 1 and 2 months. ]
The percentage of blood CD4+ T cells infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.
Change in the phenotype of endocervical and blood CD4+ T cells after treatment of schistosomiasis. [ Time Frame: 1 and 2 months. ]
Surface expression of CCR5, CD69, CD38, HLA-DR, a4b7, CCR7 and CD45RA by endocervical and blood CD4 T will be assessed using flow cytometry.
Change in genital proinflammatory cytokine levels after treatment of schistosomiasis. [ Time Frame: 1 and 2 months. ]
A predefined genital inflammation score based on genital levels of pro-inflammatory cytokines and chemokines [as per Arnold K et al, Muc Immunol, 2015] will be assessed.
Change in the cervico-vaginal microbiome after treatment of schistosomiasis. [ Time Frame: 1 and 2 months. ]
The cervico-vaginal microbiome will be assessed by 16s rRNA sequencing before and after schistosomiasis therapy.
Change in the cervico-vaginal proteome after treatment of schistosomiasis. [ Time Frame: 1 and 2 months. ]
The genital proteome will be assessed by mass spectrometry before and after schistosomiasis therapy.
Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis. [ Time Frame: 2 months. ]
The percentage of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.
Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis. [ Time Frame: 2 months. ]
The number of endocervical CD4+ T cells per cytobrush infected ex vivo by an HIV pseudovirus construct, as quantified by flow cytometry.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Positive (score above "trace") on a urine CCA rapid test
Willing to be treated with praziquantel
Willing to give informed consent, and answer short questionnaires on economic status, and sexual risk behavior.
Willing to comply with the requirements of the protocol
HIV and classical STI (see below) negative

Exclusion Criteria:

HIV infected
Malaria infected
Pregnant.
Irregular menstrual cycle, or actively menstruating at the time of genital sampling.
Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas vaginalis) or having genital ulcers
Prior hysterectomy
Deemed by physician to be unlikely to complete study protocol.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02878564

Locations

Layout table for location information

Uganda
UVRI-IAVI HIV Vaccine program
Entebbe, Wakiso, Uganda

Sponsors and Collaborators

University of Toronto

UVRI-IAVI HIV Vaccine Program, Uganda

Investigators

Layout table for investigator information

Principal Investigator:	Rupert Kaul, MD/PhD	University of Toronto

More Information

Publications:

Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, Abou M, Westmacott GR, McCorrister S, Kwatampora J, Nyanga B, Kimani J, Masson L, Liebenberg LJ, Abdool Karim SS, Passmore JA, Lauffenburger DA, Kaul R, McKinnon LR. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2016 Jan;9(1):194-205. doi: 10.1038/mi.2015.51. Epub 2015 Jun 24.

Downs JA, van Dam GJ, Changalucha JM, Corstjens PL, Peck RN, de Dood CJ, Bang H, Andreasen A, Kalluvya SE, van Lieshout L, Johnson WD Jr, Fitzgerald DW. Association of Schistosomiasis and HIV infection in Tanzania. Am J Trop Med Hyg. 2012 Nov;87(5):868-73. doi: 10.4269/ajtmh.2012.12-0395. Epub 2012 Oct 1.

Chenine AL, Shai-Kobiler E, Steele LN, Ong H, Augostini P, Song R, Lee SJ, Autissier P, Ruprecht RM, Secor WE. Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop Dis. 2008 Jul 23;2(7):e265. doi: 10.1371/journal.pntd.0000265.

Joag VR, McKinnon LR, Liu J, Kidane ST, Yudin MH, Nyanga B, Kimwaki S, Besel KE, Obila JO, Huibner S, Oyugi JO, Arthos J, Anzala O, Kimani J, Ostrowski MA; Toronto HIV Research Group, Kaul R. Identification of preferential CD4+ T-cell targets for HIV infection in the cervix. Mucosal Immunol. 2016 Jan;9(1):1-12. doi: 10.1038/mi.2015.28. Epub 2015 Apr 15.

Layout table for additonal information

Responsible Party:	Rupert Kaul, Professor, University of Toronto
ClinicalTrials.gov Identifier:	NCT02878564 History of Changes
Other Study ID Numbers:	UT-Schisto
First Posted:	August 25, 2016 Key Record Dates
Last Update Posted:	October 27, 2016
Last Verified:	October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Rupert Kaul, University of Toronto:


Schistosomiasis mansoni HIV susceptibility Genital immunology	Mucosal immunology HIV entry assay Adult women

Additional relevant MeSH terms:

Layout table for MeSH terms

Schistosomiasis Schistosomiasis mansoni Disease Susceptibility Disease Attributes Pathologic Processes Trematode Infections	Helminthiasis Parasitic Diseases Praziquantel Anthelmintics Antiparasitic Agents Anti-Infective Agents

To Top